SciSparc Ltd.

What they do

SciSparc, through its majority-owned subsidiary NeuroThera Labs Inc., develops cannabinoid-based pharmaceutical products. Its pipeline includes SCI-110 for Tourette syndrome and Alzheimer's disease with agitation, and SCI-210 for Autism Spectrum Disorder and Status Epilepticus. The company also holds a majority-owned subsidiary that sells hemp seed oil-based products on Amazon Marketplace.

Revenue drivers

• Hemp seed oil-based products — Sold via a majority-owned subsidiary on Amazon Marketplace; the only revenue-generating segment mentioned, though financial figures are not disclosed.
• SCI-110 (Tourette syndrome) — Clinical-stage asset for Tourette syndrome and Alzheimer's disease with agitation; no revenue yet as it is in development.
• SCI-210 (Autism Spectrum Disorder) — Clinical-stage asset for Autism Spectrum Disorder and Status Epilepticus; no revenue yet as it is in development.

Recent performance

The company reported net losses of $2.0M in 2016, $6.2M in 2017, $8.9M in 2018, $4.7M in 2019, and $3.5M in 2020. As of December 31, 2018, total assets were $277,000. The most recent annual report is for fiscal year ended December 31, 2025, but no financial results for that year are provided in the excerpts.

Strategy

SciSparc's strategy is to build a portfolio of cannabinoid-based pharmaceutical assets through NeuroThera, which it acquired a controlling interest in during October 2025. The company transferred its advanced clinical-stage portfolio and a 51% stake in SciSparc Nutraceuticals Inc. to NeuroThera. It continues to focus on THC and CBD-based therapies for neurological and psychiatric conditions.

Risks

• Clinical-stage failure — The company's main assets (SCI-110, SCI-210) are in clinical development; failure to demonstrate efficacy or safety could halt programs.
• Regulatory approval — Cannabinoid-based drugs face uncertain regulatory pathways in the U.S. and other markets.
• Limited cash position — With only $277,000 in total assets as of 2018 and recurring net losses, the company may need additional capital to fund operations.
• Dependence on subsidiary — Operations are largely run through NeuroThera, a TSXV-listed company, exposing SciSparc to subsidiary-level risks and market volatility.

Outlook

Management's outlook, as indicated by recent actions, is to consolidate its cannabinoid pipeline under NeuroThera and advance SCI-110 and SCI-210 through clinical development. The company also aims to monetize its hemp seed oil product line via Amazon Marketplace. No forward-looking financial guidance is provided in the excerpts.